NAD+ — the coenzyme, not a peptide, explained
NAD+ (nicotinamide adenine dinucleotide, oxidized form) is a central coenzyme in mitochondrial energy metabolism, sirtuin function, PARP-mediated DNA repair, and CD38/CD157-dependent cell signaling. It is not a peptide — NAD+ is a dinucleotide (two nucleotides joined by a pyrophosphate linkage) with a fundamentally different chemistry than the other compounds in Vivaprime's catalog. It appears in the longevity/metabolic category alongside NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide) because the biological pathway is shared, even though the molecular class is distinct. This primer covers the molecule, what NAD+ actually does biologically, the systemic-bioavailability question, the distinction between injected NAD+ and NAD+ precursors, and what researchers should honestly understand about the evidence base.
The molecule. NAD+ (oxidized) has molecular formula C₂₁H₂₇N₇O₁₄P₂ and molecular weight 663.43 Da. The molecule consists of nicotinamide linked by a pyrophosphate bridge to ribose, linked by an N-glycosidic bond to adenosine. The functional chemistry is the nicotinamide ring — it accepts a hydride (H⁻) to become NADH (reduced form) during metabolic redox reactions. Every mitochondrion in every cell of your body runs on NAD+/NADH cycling — it is one of the most fundamental metabolic cofactors in biology.
What NAD+ does biologically. Four major roles: (1) electron carrier in mitochondrial metabolism — NAD+ is reduced to NADH in glycolysis, β-oxidation, and the TCA cycle, then re-oxidized at Complex I of the electron transport chain; (2) substrate for sirtuins — the SIRT1-SIRT7 family of NAD+-consuming deacylases regulate gene expression, mitochondrial biogenesis, and cellular stress responses; (3) substrate for PARP enzymes — poly-ADP-ribose polymerases consume NAD+ during DNA damage repair, and PARP hyperactivation during DNA damage is a significant sink for cellular NAD+; (4) substrate for CD38/CD157 — cell-surface enzymes that produce signaling molecules including cyclic ADP-ribose. Declining NAD+ levels with age — documented in multiple tissues — is proposed as a contributor to mitochondrial dysfunction, sirtuin-activity loss, and impaired DNA damage response in aging.
The IV/injection NAD+ market vs the evidence base. The commercial market for injected or IV NAD+ has grown rapidly, predominantly marketed for longevity, addiction recovery, and "energy." The evidence base for systemic benefit from administered NAD+ is more limited than this marketing suggests. Key issue: NAD+ itself is a large polar molecule that is rapidly hydrolyzed in serum by CD38 and by enzymes in the liver first-pass. Systemic NAD+ administration produces transient elevation in circulating NAD+ but delivery to specific tissues (muscle, brain) is less direct than is sometimes claimed. The published literature on systemic NAD+ administration in humans is small — a handful of pilot studies, mostly open-label. For the most honest summary, Shade C. The Science Behind NMN — A Stable, Reliable NAD+ Activator and Anti-Aging Molecule. Integr Med (Encinitas). 2020;19(1):12-14 discusses why precursors (NR, NMN) are preferred for systemic delivery over NAD+ itself.
Precursors vs NAD+ itself. In the longevity-research literature, the precursor molecules — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — have a larger and more methodologically rigorous human evidence base than NAD+ itself. Both precursors are smaller molecules that are more stable in serum, have documented tissue-level bioavailability, and have been through multiple human clinical trials showing measurable elevation of tissue NAD+. Martens CR et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286 established the NR pharmacokinetic profile. For NMN, multiple human RCTs have been published since 2020. Vivaprime supplies NAD+ itself for research contexts where the native coenzyme is needed (e.g. enzyme kinetics studies in vitro); the precursors are a separate research tool class and are not interchangeable.
Research applications for NAD+ itself. The most common research use is in vitro — enzyme kinetics for sirtuins, PARPs, and CD38 all require direct NAD+ substrate. Cell culture studies frequently supplement media with NAD+ when studying NAD+-dependent pathways. In vivo, NAD+ has been administered by IV in some human pilot studies and by injection in rodent studies, but the tissue-level pharmacology is the key caveat described above. For research contexts where sustained systemic NAD+ elevation is the goal, precursor molecules are typically preferred.
Administration routes and dose ranges. Cell-culture work uses NAD+ at micromolar to millimolar concentrations in media. In vivo rodent studies have used doses in the 50-250 mg/kg range intraperitoneally. Human IV-clinic protocols typically use 500 mg to 1 gram of NAD+ in a slow infusion over 2-4 hours, typically once weekly. Subcutaneous injection (the pen-format route) has been less studied than IV — published protocols for subcutaneous NAD+ in humans are limited, and pharmacokinetic characterization is less complete than for IV. Research-context users designing NAD+ protocols should be aware of the route-of-administration pharmacokinetic gap.
Storage, stability, and handling. NAD+ is notably more sensitive to conditions than the peptides in the rest of the catalog. It is light-sensitive (chromophore at ~260 nm degrades with UV exposure), heat-sensitive (half-life at room temperature in solution is short), and particularly sensitive to freeze-thaw cycles. Lyophilized NAD+ is stable for years at -20 °C, months at 2–8 °C. The pen format's solvent system is stability-tested for in-use stability but accidental freezing, heat excursion, or prolonged light exposure can degrade the coenzyme. Discard a pen that has been frozen or has been exposed to room temperature for extended periods.
What the COA should say. A batch-specific COA for NAD+ should include (1) identity confirmation by HPLC against authentic reference material (UV detection at 260 nm is standard for NAD+ — the adenine chromophore), (2) purity by HPLC-UV typically reported as area percent at 260 nm, specification ≥ 98.0%, (3) moisture content (Karl Fischer titration) — NAD+ is hygroscopic and residual water affects molar dosing accuracy, (4) residual solvent profile per ICH Q3C, (5) endotoxin by LAL in EU/mg if the material is intended for injectable research. HPLC-MS identity confirmation is also valuable; the theoretical mass is 663.1 Da.
Research-use only. Vivaprime supplies NAD+ as research reference material for qualified researchers engaged in in-vitro laboratory work. NAD+ has not been approved by the FDA for any therapeutic indication — commercial IV NAD+ clinics operate in a compounding/wellness regulatory gray area and do not represent FDA-approved medical treatment. Nothing on this page constitutes a therapeutic, diagnostic, or consumption recommendation. Serious research readers should consider NAD+ precursor compounds (NR, NMN) for systemic-delivery applications where direct NAD+ is not required. Purchasers affirm the research-use agreement at checkout.